ClinicalTrials.gg
CompletedNCT04410315Updated Aug 17, 2022

Hyperlactatemia During and After Tumorcraniotomy

An observational study in Hyperlactatemia, Brain Tumor and Surgery, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-17.

Sponsored by Rigshospitalet, Denmark · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to investigate the association between hyperlactatemia and neurological disability, length-of-stay and mortality in patients who undergo tumorcraniotomy. The risk factors that induce lactat accumulation will also be explored.

Read the detailed description

Hyperlactatemia is a frequent occurrence in brain tumor surgery. The existing studies, however, are all retrospective, reporting varying effects on clinical outcome. One study reported new neurological deficitis, some found an association with extended hospital stay, while others found no association with outcome. It is therefore important to conduct a prospective study of hyperlactatemia in this patientgroup.

Participants in this study will follow the standard treatment protocol for tumorcraniotomy, aside from 2-3 additional, perioperative blodgas analyses and 2 standardized measurements of neurological disability.

02

Conditions studied

  • Hyperlactatemia
  • Brain Tumor
  • Surgery
  • Anesthesia
03

In context

Hyperlactatemia

50 studies on the registry are indexed under Hyperlactatemia; 7 are open to participants now.

This study's enrollment of 450 is above the median of 136 across 17 observational studies indexed under Hyperlactatemia.

Browse Hyperlactatemia studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,007 studies on the registry; 175 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing tumorcraniotomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years
  • Must undergo elective tumor craniotomy
  • Understand oral and written Danish

Exclusion criteria

Exclusion Criteria:

  • Adults with incapacity
  • Stereotactic
  • Lack of informed and signed consent to participate in study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
450 participants (actual)
Patient registry
No

Groups and cohorts

  • Tumorcraniotomy patients

    Other: Serum-lactate < 2,2 mmol/L · Other: Serum-lactate >/= 2,2 mmol/L

Interventions

  • OtherSerum-lactate < 2,2 mmol/L

    Bloodgas analysis every hour from start surgery until recovery ward discharge

  • OtherSerum-lactate >/= 2,2 mmol/L

    Bloodgas analysis every hour from start surgery until recovery ward discharge

06

What researchers measure

Primary outcomes

  1. Neurological disability

    Modified Rankin Scale (Scoring 0-6, high scores meaning worse outcome)

    Time frame: Change from baseline mRS at 30 days after surgery

Secondary outcomes

  1. Length of hospital stay

    In days from admission to discharge.

    Time frame: 1 year

  2. Mortality

    Time frame: After 30 days, 6 months and 5 years

07

Study locations

1 site
  • Department of Neuroanesthesiology, Rigshospitalet
    Copenhagen, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Feb 2022, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2020
First posted
Jun 1, 2020
StartActual
Jul 28, 2020
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Last update
Aug 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04410315
Responsible party
Alexandra Vassilieva (Principal investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Jun 1, 2020
Start date
Jul 28, 2020
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Last update
Aug 17, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion